Trial Profile
A retrospective study of gemtuzumab-ozogamicin in patients with very high risk acute myeloid leukemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Feb 2017
Price :
$35
*
At a glance
- Drugs Gemtuzumab ozogamicin (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2017 Results published in the Annals of Hematology.
- 23 Feb 2017 New trial record